Article Text

Download PDFPDF
Need for greater post-trial support for clinical trial participants assessing high-risk, irreversible treatments
  1. Alex Harris1,
  2. Frederic Gilbert2
  1. 1Department of Biomedical Engineering, The University of Melbourne, Melbourne, Victoria, Australia
  2. 2EthicsLab, School of Humanities, University of Tasmania, Hobart, Tasmania, Australia
  1. Correspondence to Dr Alex Harris, Department of Biomedical Engineering, The University of Melbourne, Melbourne, VIC 3052, Australia; alexrharris{at}gmail.com

Abstract

There are increasing numbers of clinical trials assessing high-risk, irreversible treatments. Trial participants should only expect knowledge gain to society, no personal therapeutic benefit. However, participation may lead to long-term harms and prevent future therapeutic options. While some discussion has occurred around post-trial access to treatments for participants who received therapeutic benefit, there are no post-trial support requirements for those suffering long-term consequences from trial participation. Participants may be left with significant medical, psychological, social, technical or financial needs. All trials will end at some point, regardless of their success. Subsequently, they should be designed to take into account the post-trial period including the impact on the ongoing health of a participant and their post-trial needs.

  • Clinical Trial
  • Ethics- Research
  • Genetic Therapy
  • Stem Cell Research

Data availability statement

Data sharing not applicable as no datasets generated and/or analysed for this study.

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Data availability statement

Data sharing not applicable as no datasets generated and/or analysed for this study.

View Full Text

Footnotes

  • Contributors AH conceived and drafted the paper. FG revised the paper. AH is the overall guarantor.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Provenance and peer review Not commissioned; externally peer reviewed.